Sirius Neosight

Sirius Neosight develops a technology for purifying Circulating Tumor Cells (CTC) by differential analysis of the fluidity of their membrane, and offers know-how for the culture and formation of spheroids. These CTC spheroids are then used as a new predictive tool for the effectiveness of targeted therapies in oncology. All of these steps are carried out on the basis of a simple blood sample and will be compatible with the deadlines of the current patient journey.